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Summary: The Centers for Disease Control and Prevention (CDC) is working closely with hospitals and 
local and state health departments to investigate recent increases in hospitalizations of patients with 
severe respiratory illness. Enterovirus D68 (EV-D68) has been detected in specimens from children with 
severe illness in Missouri and Illinois. Investigations into suspected clusters in other jurisdictions are 
ongoing. The purpose of this HAN Advisory is to provide awareness of EV-D68 as a possible cause of 
acute unexplained respiratory illness, and to provide guidance to state health departments and health 
care providers. Please disseminate this information to infectious disease specialists, intensive care 
physicians, pediatricians, internists, infection preventionists, and primary care providers, as well as to 




Enteroviruses are associated with various clinical symptoms, from mild to severe. EV-D68 causes 
primarily respiratory illness, although the full spectrum of disease remains unclear. EV-D68 was originally 
isolated in 1962 and, since then, has been reported rarely in the United States. Small clusters of EV-D68 
associated with respiratory illness were reported in the United States during 2009–2010.There are no 
available vaccines or specific treatments for EV-D68, and clinical care is supportive. 
 
In August 2014, a children’s hospital in Kansas City, Missouri, and one in Chicago, Illinois, notified CDC 
of increases in pediatric patients examined and hospitalized with severe respiratory illness, including 
some admitted to pediatric intensive care units. Both hospitals also reported recent increases in detection 
of rhinovirus/enterovirus, in initial screening with a respiratory virus panel. Nasopharyngeal specimens 
from patients with recent onset of severe symptoms from both facilities were sequenced by the CDC 
Picornavirus Laboratory. EV-D68 was identified in 19 of 22 specimens from Kansas City and in 11 of 14 
specimens from Chicago. Admissions for severe respiratory illness have continued at both facilities at 
rates higher than expected for this time of year. CDC has been notified by various states of similar 
clusters of respiratory illness, though confirmation of EV-D68 in these potential clusters is still under way. 
Of these severely ill patients who were confirmed positive for EV-D68 from both hospitals, all presented 
with difficulty breathing and hypoxemia, and some with wheezing. Notably, most patients were afebrile at 
presentation and throughout the hospital course. Approximately two thirds of cases had a previous 
medical history of asthma or wheezing, but both hospitals reported some patients with no known 
underlying respiratory illness. Ages ranged from 6 weeks through 16 years, with median ages of 4 and 5 
years in Kansas City and Chicago, respectively. Most patients were admitted to the pediatric intensive 
care unit. Of the 30 patients who were positive for EV-D68, two required mechanical ventilation (one of 
whom also received extracorporeal membrane oxygenation) and six required bilevel positive airway 
pressure ventilation. It should be noted that specimens from only the most severe cases have been typed 
at this time, and so these findings may not reflect the full spectrum of disease. 





Clinical Care:  
 Health care providers should consider EV-D68 as a possible cause of acute, unexplained severe 
respiratory illness, even in the absence of fever. 
 Although the findings to date have been in children, EV-D68 may also affect adults. 
 
Laboratory Testing: 
 Providers should consider laboratory testing of respiratory specimens for enteroviruses when the 
cause of respiratory infection in severely ill patients is unclear. 
 Confirmation of the presence of EV-D68 requires typing by molecular sequencing. 
 Providers may contact state or local health departments for further enterovirus typing. CDC is 
available for consultation. 
 Health departments may contact CDC for further enterovirus typing. 
 CDC is currently prioritizing respiratory specimens from patients with severe respiratory illness 
who are known to be positive for rhinovirus/enterovirus from initial screening assays. 
 Please visit the CDC EV-D68 website (http://www.cdc.gov/non-polio-enterovirus/about/EV-
D68.html) for information on specimen submission. Completion of a brief patient summary form is 
required with each specimen submission to CDC. 
Infection Control: 
 Routes of transmission for EV-D68 are not fully understood. 
 Infection control guidelines for hospitalized patients with EV-D68 infection should include 
standard precautions, and contact precautions in certain situations, as is recommended for all 
enteroviruses (http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf). 
 As EV-D68 is a cause of clusters of respiratory illness, similar to rhinoviruses, droplet 
precautions also should be considered as an interim recommendation until there is more 
definitive information available on appropriate infection control. 
 As EV-D68 is a non-enveloped virus, environmental disinfection of surfaces in healthcare settings 
should be performed using a hospital-grade disinfectant with an EPA label claim for any of 
several non-enveloped viruses (e.g. norovirus, poliovirus, rhinovirus). Disinfectant products 
should be used in accordance with the manufacturer’s instructions for the specific label claim and 
in a manner consistent with environmental infection control recommendations 
(http://www.cdc.gov/hicpac/pdf/guidelines/eic_in_HCF_03.pdf). 
Reporting: 
 Providers should report suspected clusters of severe respiratory illness to local and state health 
departments. 
 EV-D68 is not nationally notifiable, but state and local health departments may have additional 
guidance on reporting. 
 Health departments may contact CDC for epidemiologic support. Please contact Dr. Claire 
Midgley (cmidgley@cdc.gov) with brief descriptions of possible clusters. 
 
For more information:  




The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 





Categories of Health Alert Network messages:  
Health Alert  Requires immediate action or attention; highest level of importance 
Health Advisory May not require immediate action; provides important information for a specific incident or situation 
Health Update   Unlikely to require immediate action; provides updated information regarding an incident or situation 
HAN Info Service Does not require immediate action; provides general public health information 
  
##This message was distributed to state and local health officers, state and local epidemiologists, state 
and local laboratory directors, public information officers, HAN coordinators, and clinician 
organizations## 
 
